^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATI-2231

    i
    Other names: ATI-2231
    Associations

    News

    Trials
    Company:
    Aclaris
    Drug class:
    MK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=0, Withdrawn, Washington University School of Medicine | N=36 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    ATI-2231
    over2years
    ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=36, Suspended, Washington University School of Medicine | Not yet recruiting --> Suspended
    Trial suspension • Metastases
    |
    ATI-2231
    almost3years
    ATI-2231 in Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=174, Not yet recruiting, Washington University School of Medicine
    New P1 trial • New P1/2 trial • Combination therapy • Metastases
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    ATI-2231